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Abstract
Many diseases have complex genetic causes, where a set of alleles can affect the propensity of getting the disease. The
identification of such disease genes is important to understand the mechanistic and evolutionary aspects of pathogenesis,
improve diagnosis and treatment of the disease, and aid in drug discovery. Current genetic studies typically identify
chromosomal regions associated specific diseases. But picking out an unknown disease gene from hundreds of candidates
located on the same genomic interval is still challenging. In this study, we propose an approach to prioritize candidate
genes by integrating data of gene expression level, protein-protein interaction strength and known disease genes. Our
method is based only on two, simple, biologically motivated assumptions—that a gene is a good disease-gene candidate if
it is differentially expressed in cases and controls, or that it is close to other disease-gene candidates in its protein
interaction network. We tested our method on 40 diseases in 58 gene expression datasets of the NCBI Gene Expression
Omnibus database. On these datasets our method is able to predict unknown disease genes as well as identifying
pleiotropic genes involved in the physiological cellular processes of many diseases. Our study not only provides an effective
algorithm for prioritizing candidate disease genes but is also a way to discover phenotypic interdependency, cooccurrence
and shared pathophysiology between different disorders.
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Introduction
Many diseases need complex genetic and environmental factors
to occur. To find the genetic factors is important for both medical
(aiding in drug discovery and personalized treatments) and
scientific reasons (understanding mechanistic and evolutionary
aspects of pathogenesis). Genetic approaches, such as linkage
analysis (connecting loci with a tendency to be inherited together)
and association studies (mapping correlation between alleles at
different loci), have uncovered plenty of links between diseases and
particular chromosomal regions [1]. In such studies, a chromo-
somal region typically contains up to hundreds of genes, which is
too much to be useful to experimentally test potential disease
genes. For this reason it is very valuable with computational
methods to rank such candidate genes within a chromosomal
region in order of likeliness of being a disease gene.
It is fairly well confirmed that the propensity of many diseases
can be reflected in a difference of gene expression levels in
particular cell types [2]. Specifically, if a group of genes shows a
consistent pattern of different expression levels in sick subjects and
a control group, then that gene is likely a strong candidate of
playing a pathogenic role. Differences in expression levels are
detected primarily by microarray studies [2–6]. Another phenom-
enon pointed out by previous studies [7–9] is that genes associated
with the same disorder tend to share common functional features,
reflected in that their protein products have a tendency to interact
with each other. Thus another indicative trait of a disease gene is
that its protein product is strongly linked to other disease-gene
proteins. A few previous computational methods have taken this
starting point and devised methods to identify disease genes from
protein-protein interactions [10–13]. Recently, some efforts have
been made to integrate these different contributions—being
differentially expressed and being close to diseases genes, for the
identification of disease genes [14,15]. This category of methods is
based on the assumption that the protein products of disease genes
tend to be in close, in the protein interaction network, to
differentially expressed genes. Karni et al. noticed that this problem
as one equivalent to the set cover problem in graph theory, which
is NP-complete [14]. Thus it is no wonder that large-scale protein
networks can only be analyzed with approximate, greedy
algorithms. Nitsch et al. defined, what they call, a soft
neighborhood of differentially expressed genes where indirectly
connected genes also can contribute but with a weight decreasing
with the distance [15]. Our method is similar in that it combines
the same types of data, but rather than assuming that nodes
neighboring to differentially expressed genes are disease gene
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gene candidates are disease gene candidates. This difference, as we
will see, simplifies our method both conceptually and algorithmi-
cally, and makes it to a better tool for inferring pathogenic
interactions invisible in microarray data.
To outline the paper, we will start by deriving out method from
our simple assumptions of influence inspired by the Katz centrality
[16], which is similar in nature to the more well known PageRank
algorithm. To test our method, we apply it to 58 gene expression
datasets from major platforms in the NCBI Gene Expression
Omnibus (GEO) database. These datasets represent the gene
expression levels of 40 distinct diseases. Our human protein
interaction data comes from the STRING database of the human
genome and proteome. We got the data on disease genes of the
mentioned 40 diseases from the OMIM database. First, we
predicted disease genes within disease-associated loci only based
on gene expression levels and protein-protein interactions. We
used known disease genes as a benchmark to test the performance.
Then we demonstrated that inputting known disease genes
enhanced the prediction accuracy. At last, we analyzed the
globally top ranked genes to confirm that they are involved in the
physiological cellular processes of many diseases.
Results and Discussion
Overview and derivation of the method
In this section, we will derive our method for assigning a score to
genes to reflect how strong candidate disease gene a node is. The
derivation follows the same ideas as Katz’ centrality index
designed for social networks [16] and similar indices [17,18].
The starting point from the derivation is the assumption that
disease genes are typically close, in the associated protein network,
to other disease genes [7]. This is natural since proteins typically
need to form complexes, or in other ways interact to be involved in
the same (pathogenic, in this case) function, hence their associated
proteins should also have a tendency to interact. We let s =
(s1,…,sn) be our score vector over the set of genes (where si
indicates how strong i is as a disease-gene candidate), and treat the
score as a property that can be redistributed by the nodes, then our
starting point can be formalized mathematically as
stz1
i ~w
X
j=i
wijst
j ð1Þ
where wij is the strength of the coupling between the proteins of
gene i and j, w is a constant telling us how strongly i is affected by
the scores of its neighborhood, and t (in the superscript) is a
symbolic, discrete time of the redistribution of score (that we will
get rid of eventually). However, in Eq. (1), we do not include the
activity level of gene i in the disease, such as difference in
expression level. We let x =( x1,…,xn)
T represent activity level of
genes in the disease, quantified in some way. Assuming that the xi
influence the score of i in the same way as the score of the
neighbors do, we can extend Eq. (1) to
stz1
i ~dzgxizQ
X
j=i
wijst
j ð2Þ
where g is another proportionality constant. d is a constant that
represents a background probability that a vertex is a disease gene
even though in is neither differentially expressed nor connected to
other disease genes. The time in this equation is just symbolic, we
are interested in the situation when all the scores are redistributed
to a stationary state so s
t+1 = s
t. Then we drop the superscript and
write Eq. (2) on matrix format as
s~ddzgxzwWs, ð3Þ
where d = (1,…,1)
T. Which gives
s~ I-wW ðÞ
{1 ddzgx ðÞ ð 4Þ
Since we are only interested in the relative values of the scores we
can set d=1without loss of generality. If we assume the activity
levels are the same, i.e. x = d, and that the coupling strengths of
W are one or zero, and that d is negligible (i.e. that g is large),
then our score function reduces to the Katz centrality. The score
function has two free parameters—w that sets the balance
between the influence of the neighbors in the protein network
and the difference in activity level; and g that sets the relative
likelihood that a random vertex is a candidate gene. If w is small,
the difference in activity level is more important; if w is large, the
coupling to the protein neighbors is more important. Another
limit on w is that the elements of (I – wW)
21 should be non-
negative, which in practice will be the case for the w optimizing
the score (and thus no practical problem). If g is small there is less
value in the differential expression data so that there is a fair
chance a random node is associated with the disease. Ultimately,
one needs to calibrate w and g with real data where one has
another estimate of how much a gene contribute to the disease.
We will do this below, but first we consider an example to
illustrate the procedure.
In Fig. 1 we illustrate the method on an example network
designed to capture some features of disease gene networks. The
area of a node i is proportional to xi; the width of an edge is
proportional to the wij; the color indicate the score si and the
number shows the ranking of the vertices. In this case we assume g
& 1 so that d and g can be omitted in Eq. (4). In panel A we show
the situation for a low w-value—about 2% of its maximum value
(that comes from the condition that all elements of (I – wW)
–1
should be non-negative); in B we illustrate the opposite case of a
large w (98% of the maximum). We see that the w puts a priority
on being close to vertices of high score so that, for example, the
vertex that is ranked 14th in A (that it self is not differentially
expressed) becomes ranked third in B.
Disease gene prediction based on gene expression levels
and protein-protein interactions
We collected 58 human microarray datasets representing 40
diseases from the NCBI Gene Expression Omnibus (GEO). Since
GEO contains some experiments that include gene expression
measurements for more than one disease, we combined the
samples of one disease and the normal samples in the same
experiment into a disease-control set and generated 81 disease-
control sets from the 58 datasets (see Table S1). Our protein
interaction network was constructed from the STRING database,
which includes both physical and functional interactions integrat-
ed from numerous sources, including experimental repositories,
computational prediction methods and public text collections.
Eliminating self-interactions, this network consists of 1,032,872
interactions between 14,532 proteins of human genome, with their
normalized interaction weights in the STRING database.
For each microarray disease-control set, we calculated its s-core
vector by equation (4). Here we set the vector x in Eq. (4) as the
vector of the absolute values of the logarithm of the ratio of the
expression levels of this microarray set, and W as the normalized
interaction-weight matrix in STRING (See Material and Method).
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experiment (disease-control datasets) we summed up the s-score
vectors corresponding to the disease. Then we ranked the genes in
each candidate-gene set of a disease according to their s-scores and
got their r-ratios (see the Materials and Methods section). We
scanned the (w,g) parameter space in the regions Q[ 0,0:01 ½  and
g[ 0,1000 ½  using this procedure, and checked the average r-ratios
of all the known OMIM disease genes for the disease we studied. It
is noted that, since some genes are involved in different diseases,
for example, the gene IL6 is associated with Type 2 Diabetes
Mellitus, Crohn’s Disease and Juvenile Rheumatoid Arthritis, we
actually computed 348 r-ratios for the known 318 distinct OMIM
disease genes of the 40 diseases. In this way, the optimum value of
(w,g) was determined as (0.005,39), which minimized the average r-
ratios of known OMIM disease genes for the 40 diseases. For
comparison, we also fixed w and g to zero respectively, and then
searched for the optimum g and w as above. They represent the
cases that only expression data (w=0) and protein interaction
network (g=0) were used to predict disease genes, respectively.
When w = 0, the result is the same for any g .0. As for g=0,we
got optimum parameter w=0.001.
For the optimum (w,g) = (0.005,39), and the two extreme
reference values (0.001,0) and (0,1), we find average r-ratios of
0.246, 0.250 and 0.418. This result suggests that the known disease
genes were averagely ranked top 24.6% of the candidates by
integrating gene expression levels with protein interactions,
whereas they ranked top 41.8% and 25%, on average,
respectively, if only gene expression data or protein interaction
network were utilized. In Figure 2, we show the distributions of r-
ratios for the known OMIM disease genes of the 40 diseases and
the ROC curves of our algorithm, when (w,g) was taken as the
three different values respectively. It can be seen that the ranks of
gene expression levels for the disease genes are distributed almost
like the average (Figure 2A), while our s gives rise to the
enrichment of the disease genes on the top of rankings (Figure 2C).
Figure 2D shows that the ROC curve for the case of w =0i s
almost a diagonal line and the area under the ROC-curve
(AUROC) is 0.593. When protein interactions are included in the
prediction algorithm, the ROC becomes a convex curve above the
diagonal line and the AUC significantly increases to 0.767. If only
use PPI network (g = 0), the AUC is 0.764. These results indicate
the significance of our approach.
From the s-ranks of genes in each candidate set, we can predict
the top h ones associated with the disease. In Table 1, we listed
different prediction results for the known OMIM disease genes
with different h-values. A total of 28 known disease genes were
ranked first, taking a percentage of 8.1%. True positive rates
(TPR) and false positive rates (FPR) suggest the sensitivity (TPR)
and specificity (one minus the FPR) of our algorithm, respectively.
It can be seen that with the increase of h, both TPR and FPR
increase. That is, the increase of sensitivity is at the cost of the
decrease of specificity. To find a reasonable h that corresponds to a
good tradeoff between the sensitivity and specificity, in Figure 3,
we plotted the trend of the rate at which TPR changes with respect
to the change in FPR, in response to changes of h, i.e.,
DTPR=DFPRas a function of h. As shown, h=24 appeared as a
critical point where DTPR=DFPR exhibits a sudden drop from
values significantly larger than one to smaller than one. Since a
DTPR=DFPR-value smaller than one suggests that the gain of
sensitivity is not likely to compensate the loss of specificity, h=24
could be chosen as an optimal cutoff, in which the sensitivity and
specificity are 60% and 76.4% respectively. In practice, there is no
universal criterion for ‘‘best cutoff’’ but depends on the
background. In our case, we think h=30 is also an acceptable
choice, with the sensitivity and specificity 67% and 70.4%
respectively.
Out of the 40 diseases we also study three monogenic diseases,
caused by a single gene mutation. This is, of course, to evaluate
method rather than to disprove that the disease is monogenetic.
The other diseases are complex diseases believed to be associated
to variations or dysfunctions of multiple genes. As shown in
Table 2, the causing single genes of the 3 monogenic diseases,
progeria, Duchenne muscular dystrophy, and cystic fibrosis, were
successfully identified by our algorithm. While checking the
complex diseases, we found that many disease genes with highest
rankings have been reported as associated with the diseases in
other sources than OMIM. For example, genes APOE, APP,
PSEN1 and PSEN2 have been revealed being linked to autosomal
Figure 1. Illustration of the method with synthetic data. The area of the nodes is proportional to xi—the difference in expression level. The
width of the edges represents the coupling strength wij in the protein interaction network. The color of the nodes represents our score and the
numbers shows their order in this ranking. Panels A and B shows the result of two values of w—a low value of w (2% of the maximal possible) in A,
and a high value of w (98% of max). Low w-values put an emphasis on the difference in expression level; high w-values stress the proximity to other
vertices with high score. We also assume g&1.
doi:10.1371/journal.pone.0024306.g001
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studies [19]. Genome-wide association (GWA) studies have
identified some top candidate genes that consistently replicate in
Crohn’s disease, which include NOD2 and IL23R [20]. Insulin
resistance has been known strongly associated with type II
diabetes, thus genes IRS1 and IRS2, which play central roles in
insulin signal transmission, are important candidate genes
associated with type II diabetes [21]. See Table S2 for detailed
prediction results of the known disease genes.
Disease gene prediction when disease genes are partially
known
In the last section, we assume that no genes on disease loci have
been associated with the disease. Thus we only used gene
expression level to represent the activity level of gene in the
disease. In fact, genetic studies have uncovered plenty of links
between diseases and particular chromosomal regions, while some
of these disease loci have identified causative genes but the others
have not yet. For example, APOE, APP, PSEN1 and PSEN2 are
known Alzheimer’s disease associated genes located at loci
19q13.2, 21q21, 14q24.3 and 1q31–q42, respectively. Other
chromosomal regions such as 12p11.23–q13.12 and 10q24 have
been identified as related with this disease, but no specific genes
have got confirmed yet, hence disease genes on these loci are
labeled as AD5 and AD6 respectively in the OMIM morbid map
(OMIM ID 602096, 605526). Here we tried to investigate whether
the known disease genes could facilitate the prediction of the
unknowns.
For diseases with multiple known associated genes, we utilized
partially known disease genes to predict the others. Specifically, we
successively took out one gene and used the rest of the genes as
input to predict this one. We modified equation (4) as follows:
s1~(I{wW)
{1(x1zx2) ð5Þ
where x1 is the normalized vector of d + gx in equation (4), and
vector x2 was constructed such that the components correspond-
ing to the input known genes were assigned as 1 and the other
components were assigned as 0. As we did in the last section,
taking (w,g) as (0.005,39), we computed the s1-scores of genes and
then ranked the candidate genes accordingly. We found that,
compared with the results of last section which only used gene
Figure 2. Parameter dependence of prediction performance. (A) The distributions of r-ratios for the known OMIM disease genes of the 40
diseases under study, at (w,g) = (0,1), i.e., only gene expression levels were used to predict disease genes. (B) The distributions of r-ratios for the
known OMIM disease genes at (w,g) = (0.001,0), i.e., only the PPI network was used in the ranking. (C) The distributions of r-ratios for the known
OMIM disease genes at (w,g) = (0.005,39), (C) ROC curves for (w,g) = (0.005,39), (0.001,0), and (0,1), respectively.
doi:10.1371/journal.pone.0024306.g002
Figure 3. Finding a trade-off between sensitivity and specific-
ity. The variation trend of DTPR=DFPRin response to changes of h—the
number of disease genes predicted. TPR: true positive rates; FPR: false
positive rates.
doi:10.1371/journal.pone.0024306.g003
Table 1. Prediction results of our algorithm (w,g) = (0.005,39)
for the known OMIM disease genes of the 40 diseases under
study.
h TP TPR FPR TPR/FPR
1 28 0.081 0.009 9
10 120 0.345 0.098 3.520
15 163 0.468 0.147 3.184
24 208 0.600 0.236 2.542
30 233 0.670 0.296 2.264
h: number of genes on the top of the candidate ranking that was predicted as
disease-associated; TP: true positive numbers, i.e., number of known disease
genes that was predicted as disease-associated; TPR: true positive rates; FPR:
false positive rates.
doi:10.1371/journal.pone.0024306.t001
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and the r-ratio decreased to 21.11 (See Table S2). In Figure 4 we
show the performance comparison of the predictions in situations
of inputting partial known disease genes or not. It can be seen that
when partial known disease genes were utilized in the prediction,
the area under the ROC-curve (AUROC) increased to 0.80.
These results suggest that our algorithm performed better when
more information about the disease was known.
As listed in Table S3, among the diseases we studied, 123 genes
have not been identified on known disease-associated chromo-
somal regions. Similar as we did above, we tried to predict the
unknown genes using all the known disease genes. Here we
present our results on Alzheimer’s disease (AD) as an example.
The OMIM morbid map collected 15 known AD-associated
genes (see Table S2) and 12 unknown genes denoted as
AD5,AD16. Using all the known genes as input, we ranked
the candidates on each chromosmal region of unknown genes by
their s1-scores. Then starting from the top of each candidate rank,
we picked a gene and conducted literature search in PubMed to
explore possible links of this gene to Alzheimer’s disease. We
listed our predictions of AD-associated genes that have found
literature supports in Table 3 and the evidences in literature as
follows:
N VDR: Vitamin D3 is known to be involved in neuroprotection.
Vitamin D receptor (VDR) gene can influence the affinity of
vitamin D3 to its receptor and thus associated with AD [22].
N BTRC: BTRC mediates the ubiquitination and subsequent
proteasomal degradation of target proteins. Defects in
ubiquitin-dependent proteolysis have been shown to result in
a variety of neurodegenerative diseases [23].
N TRDMT1: TRDMT1is a DNA methylation protein involved
in aging-related process [24].
N PCNA: Expression of PCNA was observed in glial cells and
neurons, with a trend to increased expression in association
with higher burdens of Alzheimer-type pathology [25].
N ICAM1: Monocytic cell adhesion molecules are decreased in
AD patients [24]. Elevated cerebrospinal fluid soluble ICAM-1
is associated with lower perfusion levels in the parietal cortex of
cognitively intact elderly [27].
N NOS3: Expression of the NOS3 gene has been demonstrated
in degenerating neurons and glial cells in brains with AD [28].
N CDKN2A: CDKN2A is a promising new candidate gene
potentially contributing to AD susceptibility on chromosome
9p [29].
N FGFR1: Gene expression of FGFR1 was up-regulated in
amyloid beta protein-injected mouse model for Alzheimer
disease [30].
N S100A4: S100-mediated signal transduction pathways play an
important role in nervous system function or disease, and
S100A4 has been shown implicated in neurological diseases
[31].
N PRDX6: Oxidative stress conditions exist in AD and
peroxiredoxin 6 is an important antioxidant enzyme in human
brain defenses [32].
N TF: Epistatic interaction between rs1049296 (P589S) in the
transferrin gene (TF) and rs1800562 (C282Y) in the hemo-
chromatosis gene (HFE) results in significant association with
risk for AD [33].
N COX7B: Amyloidbetapeptide (A beta) is implicated in
neuronal cell death in Alzheimer’s disease. Studies on AD
suggest that COX7B mRNA is increased in AD brains and its
overexpression in cells enhances A beta(1-40)-toxicity [34].
Table 3 shows that almost half of the predicted disease genes are
ranked first in the list of candidate genes, suggesting a good
performance of our algorithm.
Analysis of the globally top ranked genes
For each disease under study, we computed s1 for all vertices by
equation (5) using gene expression levels and all known disease
genes as input. Then we neglected, for the moment, the expression
data and ranked genes in the protein interaction network
according to their s1-values. It was found that the top genes
overlapped in most diseases. For example, gene AKT1 and TP53
Table 2. Selected prediction results for disease genes in three
monogenic diseases and complex diseases, respectively.
Disease MeSH Gene name Gene loci s-rank
Progeria LMNA 1q21.2 4
Muscular Dystrophy, Duchenne DMD Xp21.2 2
Cystic Fibrosis CFTR 7q31.2 8
Alzheimer Disease APOE 19q13.2 3
APP 21q21 4
PSEN1 14q24.3 4
PSEN2 1q31-q42 15
Crohn Disease IL6 7p21 1
IL23R 1p31.3 3
NOD2 16q12 4
Diabetes Mellitus, Type 2 IL6 7p21 1
PPARG 3p25 1
IRS1 2q36 2
IRS2 13q34 3
s-rank: ranks of candidate genes according to their s-values when (w,g)=
(0.005,39).
doi:10.1371/journal.pone.0024306.t002
Figure 4. ROC curves for the predictions of disease genes. Here
we restrict the analysis to diseases with at least two known associated
genes.
doi:10.1371/journal.pone.0024306.g004
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respectively.
We took out the top 200 s1-ranked genes of each disease and
got 1330 genes in total, 107 of which overlapped in at least 90%
diseases under study (see Table S4 for detail). (In the table we
called them top ranked genes.) However, only 23 of them are
disease genes of these 40 diseases. To explore the implications of
the top ranked genes to diseases, we conducted gene ontology
(GO) and pathway enrichment analysis. We used the P-value to
quantitatively measure whether this top ranked gene group is
more enriched with genes of a specific Gene ontology (GO) term
or genes involved in a particular pathway than what would be
expected by chance. Given significance level a=0.05,aP-value
smaller than a demonstrates low probability that the genes of
same GO term or pathway appear in the group by chance. As
listed in Table 4, this top ranked group is significantly enriched
with genes whose GO terms are response to stimulus and stress,
regulation of cell differentiation, proliferation and death, and
immune process. These biological processes are highly associated
with the progress of diseases, especially cancers. When mapping
these genes onto KEGG pathways, we found that a total of 42
disease pathways are significantly enriched with genes in this
group, 17 of which are among the 40 diseases under study (see
Table S5). In addition, these top 1% s-ranked genes are
significantly involved in 32 pathways of cellular processes,
organismal systems and environmental information processing
(see Table S6). It has been known that most of these pathways are
related with diseases.
Next, we studied the correlation between s1-rank and the
pleiotropic effects of disease genes. Disease gene pleiotropy refers
to the ability of different mutations within the same gene to cause
different pathological effects. For each of the 318 known disease
genes of the 40 diseases under study, we searched the OMIM
morbid map and got the number of different diseases shared with
this gene. Figure 5 displays the negative correlation between
average s1-rank of known disease genes and the number of shared
diseases (Pearson’s correlation coefficient is –0.906), suggesting
that our algorithm ranks genes with more pleiotropy higher. This
phenomenon confirmed our observation above that the globally
top ranked genes tend to be involved in multiple diseases.
To investigate whether the top ranked genes are intrinsic for
diseases, for each of the 81 disease-control sets, we generated ten
random counterparts of gene expression levels and known disease
gene sets, respectively. Replacing vectors x1 and x2 in equation (5)
with those corresponding to their random counterparts, we
computed the s1-scores of genes by equation (5). As we did above,
we took out the top 200 s1-ranked genes of each random
counterpart. Almost all the genes appeared at least once in a top
200 list, in which only two genes overlapped in at least 35%
random counterparts. In contrary to what computed from real
gene expression levels and known disease gene sets of diseases,
these top ranked genes exhibited very low extent of overlapping.
This result suggests that only real data reflecting the activity levels
of genes in disease status could help to correctly pick out the genes
with the features we observed above. Thus the globally top s1-
ranked genes are inherently correlated with diseases.
In summary, although only a small fraction (21.5%) are disease
genes in the OMIM database, these globally top ranked genes are
significantly involved in multiple disease processes. This is in line
with previous findings that comorbidity between different diseases
is linked by phenotypic interdependency (via protein interactions)
and common pathophysiology (being differentially expressed in
Table 3. Alzheimer’s disease (AD) associated genes predicted by our algorithm that have found literature supports.
Unknown AD genes in OMIM morbid Predicted AD-associated genes by our algorithm
No
Gene Symbol
in OMIM morbid OMIM ID Gene loci Gene ID Gene Symbol Gene loci s1-rank
1 AD5 602096 12p11.23–q13.12 7421 VDR 12q13.11c 3
2 AD6 605526 10q24 8945 BTRC 10q24.32a 4
3 AD7 606187 10p13 1787 TRDMT1 10p13a 9
4 AD8 607116 20p 5111 PCNA 20p12.3c 2
5 AD9 608907 19p13.2 3383 ICAM1 19p13.2c 1
6 AD10 609636 7q36 4846 NOS3 7q36.1c–q36.1d 1
7 AD11 609790 9p22.1 1029 CDKN2A 9p21.3c 2
8 AD12 611073 8p12–q22 2260 FGFR1 8p12a 1
9 AD13 611152 1q21 6275 S100A4 1q21.3c 3
10 AD14 611154 1q25 9588 PRDX6 1q25.1a 1
11 AD15 611155 3q22–q24 7018 TF 3q22.1e 1
12 AD16 300756 Xq21.3 1349 COX7B Xq21.1a 3
doi:10.1371/journal.pone.0024306.t003
Table 4. Selected significantly enriched GO terms for the top
s1-ranked genes.
GO ID GO Term
Mapped
genes
Total
genes
GO:0050896 response to stimulus 68 6192
GO:0006950 response to stress 53 2538
GO:0002376 immune system process 44 1436
GO:0030154 cell differentiation 43 2008
GO:0042127 regulation of cell proliferation 40 946
GO:0010941 regulation of cell death 44 1042
All reported genes are significant with a P-value less than 0.001.
doi:10.1371/journal.pone.0024306.t004
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could be bridges to relate different diseases with each other.
Conclusions
This work has discussed a method to integrate microarray-based
global gene expression data and genome scale protein-protein
interaction network for the prioritization of candidate disease
genes. According to the observation that disease genes tend to be
close to other disease genes in the associated protein network, we
proposed a score inspired by the Katz centrality. This score needs
to be calibrated by only two parameters. These parameters have a
clear biological interpretation so their optimal values can give us
some further insights. The first parameter w sets the relative
importance of the difference in expression level and closeness in
the protein interaction network. The second parameter g
represents chance for a node that is not differentially expressed
to be a disease gene. The optimum is reached for (w,g)=
(0.005,39), which is well in the interior of the parameter space in
both dimensions—0# w ,0.01 and 0# g ,0.01. This means that
both the protein interaction network and the differential
expression contain information that can be exploited in disease-
gene ranking, as hypothesized. On the other hand, we see that
putting Ø=0 worsen the performance much more than putting
g=0, which suggest that there is more information for the benefit
of predicting unknown disease genes in the interaction compared
with the microarray data, at least with our setup. Furthermore, we
were able to increase our method’s performance by including
partial information about known disease genes. Also, when we did
not consider specific gene loci and ranked all genes globally by our
score, we could identify genes that show high extent of pleiotropy
and participate in the physiological pathogenic processes of many
diseases [35]. In addition, the successful identification of the
common genes involved in many diseases in the context of
network indicates the phenotypic interdependency, cooccurrence
and shared pathophysiology between different disorders. This
study provides a novel, effective and easy-implemented algorithm
for the prioritization of candidate disease genes. It can also be used
to compare the connection between pathological phenotypes
through their common genetic factors.
Materials and Methods
Gene expression data collection and integration
We collected human microarray datasets from the NCBI Gene
Expression Omnibus (GEO) [36] and restricted to using only those
curated and reported in the GEO Datasets (GDS). Our criteria for
the selection of a dataset are as follows:
1. It used one of the four most common platforms: HG_U95A,
HG_U95Av2, HG_U133A, and HG_U133_Plus2.
2. It was assigned to human disease conditions, with healthy
samples as the control condition. In addition, at least one
disease gene of this disease is known from the OMIM database.
The samples were not treated by drugs.
3. It did not include time-series data.
4. It included at least four disease samples and four control
samples.
A total of 58 datasets was found to satisfy the criteria. We
combined the samples of one disease and the normal samples in
the same experiment into a disease-control set. Since GEO
contains some experiments that include gene expression measure-
ments for more than one disease, 81 disease-control sets were
obtained from the 58 datasets. Mapping the disease description in
the GDS curation to their MeSH (Medical Subject Headings)
terms corresponded to 40 distinct diseases (see Table S1).
To integrate gene expression data from different platforms, we
mapped the probe sets of the platforms to Entrez Gene ID. This
process yielded a set of 9308 genes common to all four platforms
for our further study. For each gene in a dataset, we calculated the
average expression level for probe sets associated to this gene, and
converted the expression value to its rank among expression values
of the sample. The rank transformation allows for the direct
comparison of gene expression levels across various microarray
experiments [37,38]. To identify differentially expressed genes, for
each gene in a disease-control set, we calculated the log ratio of the
average rank of disease samples versus the average rank of control
samples. We take the absolute value of the log ratio as a measure
of the activity level of the gene in this disease.
Protein-protein interaction data
Protein interactions between human proteins were downloaded
from the version 8.3 of STRING [39]. STRING includes both
physical and functional interactions integrated from numerous
sources, including experimental repositories, computational predic-
tion methods and public text collections. It uses a scoring system to
weight the evidence of each interaction. STRING includes the
interactions between 14532 proteins of human genome. We
normalized the interaction scores in STRING to the interval [0,1].
Disease-gene dataset
We searched the Morbid map of the Online Mendelian
Inheritance in Man (OMIM) database [40] and identified 359
genes associated with the 40 distinct diseases in our microarray
data, in which one disease was associated with at least one gene. As
listed in Table S2, the disease with the most known causing genes
is cardiomyopathy, with 32 disease genes known. A total of 318 of
the 359 genes were found to present in the protein-protein
interaction network constructed from STRING, and these genes
were used to validate our algorithm (see Table S2).
Candidate genes
We downloaded human gene location data from the FTP
server of NCBI’s MapViewer [41]. This source includes the
Figure 5. Correlation between the importance and pleiotropy.
We measure the s1-score averaged over bins of the number of shared
diseases for that particular gene (as a measure of the strength of
pleiotropy).
doi:10.1371/journal.pone.0024306.g005
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human genes. For each of the 318 known disease genes, we
determined a set of about 100 candidate genes, including this
disease gene, which locate at, or near to the cytogentic loci of the
disease gene.
Disease gene prediction
Most of our algorithm is already detailed in the section
Results and Discussion. We mention, however, that we solved
equation (4) by Jacobi iteration algorithm. Furthermore, for
each disease-control dataset k,a ns-vector was calculated by
equation (4). In cases when one disease corresponds to more
than one experiment (disease-control datasets), the score
vectors for a given disease were added together to obtain a
combined s-score. Then the genes in each candidate gene set of
a disease can be ranked according to their s-cores, while the top
h genes in the ranking could be predicted as associated with this
disease.
Performance measure
The known disease genes in the OMIM database were used to
determine parameters w and g, as well as to assess the
performance of our algorithm. For a known disease gene in a
candidate gene set of size N,i fi t ss-rank calculated by our
algorithm is r,t h e ni t sr-ratio defined as r/N, could reflect how
strong this gene is predicted as a disease gene. We determined
parameters w and g as those minimized the average r-ratios of the
known OMIM disease genes.
We then applied the receiver operating characteristics (ROC)
analysis [42] to evaluate our algorithm. We took the top h genes
in each of our candidate gene rankings as disease genes (positive).
Changing h from 1 to 100, we computed the true positive rates
(TPR) and false positive rates (FPR) of our predictions. Then a
ROC curve is obtained by plotting TPR versus FPR for the h-
values. A ROC curve gives an overview of the overall
performance of a classifier. When comparing ROC-curves of
different classifiers, good curves lie closer to the top left corner
and the worst case is a diagonal line that represents a strategy of
random guessing. The total area under the ROC-curve
(AUROC) is a measure of the performance of the classifier.
The area lies in the interval [0.5,1] and larger area indicates
better performance. On the other hand, the values of TPR and
FPR suggest the sensitivity and specificity of the classifier,
respectively. Larger TPR and smaller FPR correspond to both
higher sensitivity and specificity. Usually, the increase of
sensitivity is at the cost of the decrease of specificity. In our case,
with the increase of h, both TPR and FPR increase. Only when
the increase of TPR is faster than that of FPR, i.e.
DTPR=DFPRw1, taking the larger h is cost-efficient. Thus the
optimal trade-off value of h satisfies:
DTPR
DFPR
h ðÞ ~
TPR h ðÞ {TPR h{1 ðÞ
FPR h ðÞ {FPR h{1 ðÞ
w1a n d
DTPR
DFPR
hz1 ðÞ ~
TPR hz1 ðÞ {TPR h ðÞ
FPR hz1 ðÞ {FPR h ðÞ
v1
is a natural cutoff position in the candidate ranking that
corresponds to a optimum tradeoff between the sensitivity and
specificity.
Pathway data and pathway enrichment analysis
We downloaded pathway data from the FTP service of KEGG
[43] (Kyoto Encyclopedia of Genes and Genomes) on June 21,
2011. The KEGG PATHWAY section is a collection of manually
drawn pathway maps representing the information on the mole-
cular interaction and reaction networks. The ‘‘hsa_pathway.list’’
file in this section includes a list of the known proteins in H. sapiens’
genome and the corresponding pathways that they are involved in.
We used pathway enrichment analysis [44] to determine
whether a pathway is significantly enriched with a group of
genes. Specifically, we compare with a hypergeometric
cumulative distribution [45] to measure whether a pathway is
more enriched with the gene group under study than would be
expected by chance. Given significance level a=0.05, a P-value
smaller than a suggests a low probability that the gene group
appear in the pathway by chance, i.e.,t h ep a t h w a yc a nb e
regarded as being significantly influenced by this group of genes
under the null-hypothesis of a hypergeometric cumulative
distribution.
Generating random counterparts of gene expression
levels of diseases and known disease gene sets
For each disease-control set, we selected a pair of genes
randomly and exchanged their activity values in the disease (the
log ratio of the average rank of disease samples versus the average
rank of control samples). Repeating this process a sufficiently large
number of times gave us a randomly reshuffled vector of gene
expression levels for the disease-control set, which we used as a
random reference of gene expression levels for this disease.
As the known disease genes of the 40 diseases under study are at
least 1 and at most 32, we generated an array of random integers
chosen from the continuous uniform distribution over the interval
[1,32] to simulate the numbers of disease genes. Then, for each
random number R in the array, we selected R genes randomly in
the protein interaction network as random counterparts of known
causing genes of the disease.
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